
Partex offers a digital pharma platform that helps life-science organizations accelerate drug development and manage drug assets. It combines AI/ML-driven discovery and portfolio management with validation via wet-lab experiments and real-world evidence. The platform supports patient-mediated data ownership and rewards for research participation while enabling pharma and biotech partners to develop and license drug assets. Partex operates as an AI-enabled B2B digital pharma platform with global operations and multi-continent offices. Its core technologies include machine learning, AI-driven asset management, and integrations with laboratory validation workflows and real-world evidence sources.

Partex offers a digital pharma platform that helps life-science organizations accelerate drug development and manage drug assets. It combines AI/ML-driven discovery and portfolio management with validation via wet-lab experiments and real-world evidence. The platform supports patient-mediated data ownership and rewards for research participation while enabling pharma and biotech partners to develop and license drug assets. Partex operates as an AI-enabled B2B digital pharma platform with global operations and multi-continent offices. Its core technologies include machine learning, AI-driven asset management, and integrations with laboratory validation workflows and real-world evidence sources.
What they do: AI-enabled digital pharma platform for drug discovery, portfolio/asset management, and lab/RWE validation
Founded: 2021
Headquarters: Eschborn, Germany
Recent funding: Seed (Jan 9, 2024)
Known investors: C3 Venture Capital; EIT Digital Accelerator
Drug discovery and drug-asset portfolio management for pharmaceutical and biotech organisations.
2021
Biotechnology
Investors in this round reported as C3 Venture Capital and EIT Digital Accelerator
“Backed by venture and accelerator investors (C3 Venture Capital; EIT Digital Accelerator)”